The application of tyrosine kinase inhibitors and targeted immunotherapy has revolutionized the therapeutic strategies and clinical outcome for BCR::ABL1-positive B-cell acute lymphoblastic leukemia (BCR::ABL1+ B-ALL). The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.